Hope for kids with rare blood disorder: new pill under study

NCT ID NCT06934967

First seen Dec 08, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests a medicine called iptacopan in 12 children aged 2 to 18 who have a rare blood disease called PNH. The goal is to see how the drug works in their bodies and if it is safe. PNH causes red blood cells to break apart, and this treatment aims to control that damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Childrens Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104 4399, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Novartis Investigative Site

    RECRUITING

    Brasília, Federal District, 70684-831, Brazil

  • Novartis Investigative Site

    RECRUITING

    Natal, Rio Grande do Norte, 59012 300, Brazil

  • Novartis Investigative Site

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-003, Brazil

  • Novartis Investigative Site

    RECRUITING

    Santo André, São Paulo, 09090-401, Brazil

  • Novartis Investigative Site

    RECRUITING

    São Paulo, São Paulo, 01323001, Brazil

  • Novartis Investigative Site

    RECRUITING

    São Paulo, São Paulo, 04038-002, Brazil

  • Novartis Investigative Site

    RECRUITING

    Cali, Valle del Cauca Department, 760012, Colombia

  • Novartis Investigative Site

    RECRUITING

    Berlin, 13353, Germany

  • Novartis Investigative Site

    RECRUITING

    Genova, GE, 16147, Italy

  • Novartis Investigative Site

    RECRUITING

    Utrecht, 3584 CX, Netherlands

  • St Jude Childrens Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.